T1	Measurement 16 30	calculated PRA
T2	Value 31 61	higher than 0% per solid phase
T3	Procedure 131 150	single antigen test
T4	Value 71 87	anti-HLA class I
T5	Value 71 79;97 105	anti-HLA class II
*	OR T5 T4
T6	Scope 71 104	anti-HLA class I and / or class I
R1	Has_scope Arg1:T3 Arg2:T6	
T7	Procedure 152 159	Luminex
R2	Subsumes Arg1:T3 Arg2:T7	
T8	Procedure 220 246	graft from a cadaver donor
T9	Condition 249 262	Identical HLA
T10	Procedure 183 194	Cross Match
T11	Value 164 172	Positive
R3	Has_value Arg1:T10 Arg2:T11	
T12	Procedure 312 334	solid organ transplant
T13	Temporal 303 311	previous
T14	Procedure 346 363	kidney transplant
R4	Subsumes Arg1:T12 Arg2:T14	
T15	Qualifier 393 400	another
T16	Procedure 401 423	solid organ transplant
T17	Temporal 424 437	concomitantly
R5	Has_qualifier Arg1:T16 Arg2:T15	
R6	Has_temporal Arg1:T16 Arg2:T17	
R7	Has_temporal Arg1:T12 Arg2:T13	
T18	Condition 440 464;479 488	Glomerular primary focal sclerosis
T19	Condition 440 450;469 488	Glomerular segmental sclerosis
*	OR T18 T19
T20	Condition 490 531	Atypical hemolytic uremic syndrome (aHUS)
T21	Condition 534 578	thrombotic thrombocytopenic purpura syndrome
*	OR T20 T21
T22	Condition 618 641	Hepatitis B virus (HBV)
T23	Condition 673 690	Hepatitis C virus
T24	Procedure 701 711	PCR result
T25	Value 692 700	positive
R8	Has_value Arg1:T24 Arg2:T25	
T26	Qualifier 595 602	chronic
T27	Qualifier 651 657	active
R9	Has_qualifier Arg1:T22 Arg2:T26	
R10	Has_qualifier Arg1:T23 Arg2:T27	
T28	Scope 692 711	positive PCR result
*	OR T23 T22
T29	Scope 595 690	chronic infection with Hepatitis B virus (HBV) and / or active infection with Hepatitis C virus
R11	Subsumes Arg1:T29 Arg2:T28	
T30	Temporal 713 738	at the time of transplant
R12	Has_temporal Arg1:T29 Arg2:T30	
T31	Condition 780 814	Human Immunodeficiency Virus (HIV)
T32	Condition 838 856	systemic infection
T33	Qualifier 831 837	active
R13	Has_qualifier Arg1:T32 Arg2:T33	
T34	Drug 903 914	antibiotics
R14	AND Arg1:T32 Arg2:T34	
T35	Multiplier 875 899	continued administration
R15	Has_multiplier Arg1:T34 Arg2:T35	
T36	Condition 935 943	neoplasm
T37	Negation 944 950	except
T38	Condition 951 972	localized skin cancer
R16	Has_negation Arg1:T38 Arg2:T37	
R17	AND Arg1:T36 Arg2:T38	
T39	Qualifier 1029 1035	severe
T40	Condition 1036 1042	anemia
R18	Has_qualifier Arg1:T40 Arg2:T39	
T41	Measurement 1044 1054	hemoglobin
T42	Value 1055 1063	<6g / dl
R19	Has_value Arg1:T41 Arg2:T42	
T43	Condition 1066 1076	leukopenia
T44	Measurement 1078 1081	WBC
T45	Value 1082 1093	<2500 / mm3
R20	Has_value Arg1:T44 Arg2:T45	
T46	Scope 1044 1063	hemoglobin <6g / dl
T47	Scope 1078 1093	WBC <2500 / mm3
R21	Subsumes Arg1:T43 Arg2:T47	
T48	Scope 1029 1042	severe anemia
R22	Subsumes Arg1:T48 Arg2:T46	
T49	Condition 1104 1120	thrombocytopenia
T50	Measurement 1122 1131	platelets
T51	Value 1132 1145	<80,000 / mm3
R23	Has_value Arg1:T50 Arg2:T51	
T52	Scope 1122 1145	platelets <80,000 / mm3
R24	Subsumes Arg1:T49 Arg2:T52	
*	OR T43 T49 T48
T53	Condition 1166 1190	hemodynamically unstable
T54	Measurement 1209 1226	hemoglobin levels
T55	Value 1226 1235	> 6g / dL
R25	Has_value Arg1:T54 Arg2:T55	
T56	Condition 1252 1272	intestinal pathology
T57	Condition 1276 1291	severe diarrhea
T58	Observation 1297 1320	may decrease absorption
*	OR T56 T57
T59	Scope 1252 1291	intestinal pathology or severe diarrhea
R26	Has_context Arg1:T59 Arg2:T58	
T60	Condition 1373 1389	hypersensitivity
T61	Drug 1404 1428	drugs used in this study
R27	AND Arg1:T60 Arg2:T61	
T62	Competing_trial 1431 1537	Patients who have received any investigational drug in the 30 days prior to their inclusion in this study.
T63	Pregnancy_considerations 1539 1756	Potentially fertile women who do not agree to use reliable contraceptive measures during the trial, who are pregnant, breastfeeding or who present a positive pregnancy test at the time of their inclusion in the study.
T64	Observation 1775 1791	legally detained
T65	Visit 1798 1818	official institution
R28	AND Arg1:T64 Arg2:T65	
